Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression

<p>Figure S.6</p>

সংরক্ষণ করুন:

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক:	Xufeng Lu (14960724) (author)
অন্যান্য লেখক:	Dazhuan E. Xin (14960727) (author), Juanjuan K. Du (14960730) (author), Quanli C. Zou (14960733) (author), Qian Wu (14960736) (author), Yanan S. Zhang (14960739) (author), Wenhai Deng (14960742) (author), Jicheng Yue (14960745) (author), Xing S. Fan (14960748) (author), Yuanyuan Zeng (9330065) (author), Xiaju Cheng (14960751) (author), Xue Li (14960754) (author), Zhaoyuan Hou (14960757) (author), Man Mohan (14960760) (author), Ting C. Zhao (14960763) (author), Xiaomei Lu (14960766) (author), Zhijie Chang (14960769) (author), Liyan Xu (14960772) (author), Yu Sun (14960775) (author), Xiongbing Zu (14960778) (author), Yu Zhang (14960781) (author), Y. Eugene Chinn (14960784) (author)
প্রকাশিত:	2025
বিষয়গুলি:	Cancer Cancer Biology Immuno-oncology Gynecological Cancers Uterine cancer Immunotherapy Combination immunotherapy Oncogenes & Tumor Suppressors Tumor suppressor genes
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
অনুযায়ী: Xufeng Lu (14960724)
প্রকাশিত: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
অনুযায়ী: Xufeng Lu (14960724)
প্রকাশিত: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
অনুযায়ী: Xufeng Lu (14960724)
প্রকাশিত: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
অনুযায়ী: Xufeng Lu (14960724)
প্রকাশিত: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
অনুযায়ী: Xufeng Lu (14960724)
প্রকাশিত: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
অনুযায়ী: Xufeng Lu (14960724)
প্রকাশিত: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
অনুযায়ী: Xufeng Lu (14960724)
প্রকাশিত: (2025)

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
অনুযায়ী: Francisco Exposito (16721403)
প্রকাশিত: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
অনুযায়ী: Francisco Exposito (16721403)
প্রকাশিত: (2025)

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
অনুযায়ী: Francisco Exposito (16721403)
প্রকাশিত: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
অনুযায়ী: Francisco Exposito (16721403)
প্রকাশিত: (2025)

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
অনুযায়ী: Francisco Exposito (16721403)
প্রকাশিত: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
অনুযায়ী: Renumathy Dhanasekaran (14962092)
প্রকাশিত: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
অনুযায়ী: Daniel S. Green (15047598)
প্রকাশিত: (2025)

Supplementary Figure 1 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
অনুযায়ী: Bo Yan (15062907)
প্রকাশিত: (2025)

Supplementary Figure 2 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
অনুযায়ী: Bo Yan (15062907)
প্রকাশিত: (2025)

Supplementary Figure 3 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
অনুযায়ী: Bo Yan (15062907)
প্রকাশিত: (2025)

Supplementary Figure 4 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
অনুযায়ী: Bo Yan (15062907)
প্রকাশিত: (2025)

Supplementary Table 1 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
অনুযায়ী: Bo Yan (15062907)
প্রকাশিত: (2025)

Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
অনুযায়ী: John Powderly (15026168)
প্রকাশিত: (2025)

Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
অনুযায়ী: John Powderly (15026168)
প্রকাশিত: (2025)

Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
অনুযায়ী: John Powderly (15026168)
প্রকাশিত: (2025)

Figure S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
অনুযায়ী: John Powderly (15026168)
প্রকাশিত: (2025)

Figure S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
অনুযায়ী: John Powderly (15026168)
প্রকাশিত: (2025)

Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
অনুযায়ী: John Powderly (15026168)
প্রকাশিত: (2025)

Table 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
অনুযায়ী: John Powderly (15026168)
প্রকাশিত: (2025)

Table 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
অনুযায়ী: John Powderly (15026168)
প্রকাশিত: (2025)

Table S1 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
অনুযায়ী: Morgane Lecointre (21652429)
প্রকাশিত: (2025)

Table S2 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
অনুযায়ী: Morgane Lecointre (21652429)
প্রকাশিত: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
অনুযায়ী: Xiaodong Shu (16721586)
প্রকাশিত: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
অনুযায়ী: Xiaodong Shu (16721586)
প্রকাশিত: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
অনুযায়ী: Xiaodong Shu (16721586)
প্রকাশিত: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
অনুযায়ী: Xiaodong Shu (16721586)
প্রকাশিত: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
অনুযায়ী: Xiaodong Shu (16721586)
প্রকাশিত: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
অনুযায়ী: Xiaodong Shu (16721586)
প্রকাশিত: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
অনুযায়ী: Xiaodong Shu (16721586)
প্রকাশিত: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
অনুযায়ী: Xiaodong Shu (16721586)
প্রকাশিত: (2025)

Supplementary Data1 from Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and Plasma
অনুযায়ী: Namsoo Kim (21718000)
প্রকাশিত: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
অনুযায়ী: Diwakar Davar (15023480)
প্রকাশিত: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
অনুযায়ী: Diwakar Davar (15023480)
প্রকাশিত: (2025)